Pharma Stability: Insights, Guidelines, and Expertise
Change control refers to a structured process to evaluate and implement changes that could impact product quality, stability, safety, or regulatory status. In the context of stability testing, changes may include:
Click to read the full article.
Without formal SOPs, deviation management becomes ad hoc and error-prone. Regulatory authorities expect every site to have a documented procedure that clearly outlines how to:
Click to read the full article.
Deviation and CAPA systems are designed to detect, investigate, correct, and prevent issues in pharmaceutical processes. But unless reviewed critically by QA, these systems can become mere documentation exercises. Here’s what a robust QA review ensures:
Click to read the full article.
Stability analysts often focus heavily on data generation and sample handling, but when a deviation occurs, their response determines how well the issue is contained and rectified. Poor investigations, inadequate documentation, or irrelevant CAPAs can attract observations from agencies like the USFDA or EMA. Hence, structured training ensures analysts understand:
Click to read the full article.
Before attempting to justify study continuation, it is essential that your stability protocol clearly defines what constitutes a “significant deviation”. Common examples include:
Click to read the full article.
Excursions — deviations from specified environmental conditions in stability chambers — can compromise the reliability of stability data and product quality. While a single deviation may be justifiable, regulators scrutinize recurrence trends to identify deeper process failures.
Click to read the full article.
Excursions, especially in stability chambers, may impact the validity of stability data. Regulatory bodies are increasingly raising concerns over not just individual deviations, but over trends of recurring events. If a chamber crosses the specified 25°C/60% RH or 30°C/65% RH range multiple times in a quarter, it is seen as a red flag.
Click to read the full article.
In the tightly regulated pharmaceutical industry, it’s not enough to just initiate corrective and preventive actions (CAPA) — you must prove they are effective. In stability operations, especially where temperature excursions or equipment deviations can jeopardize long-term data, effective CAPA monitoring ensures the integrity of your product shelf-life determinations. Regulatory bodies like USFDA and EMA scrutinize how you track CAPAs and assess their impact across the product lifecycle.
Click to read the full article.
In the pharmaceutical industry, stability excursions can directly compromise the integrity of long-term data, and therefore, the shelf-life claims of a product. Whenever a deviation such as a temperature or humidity excursion is identified, an effective investigation must not only find the cause — it must categorize the root cause appropriately. Regulatory agencies, including USFDA and EMA, demand documented justification for both the cause and the classification.
Click to read the full article.
In today’s globalized pharmaceutical operations, companies often manage manufacturing and stability testing activities across multiple facilities or contract partners. When a deviation occurs—whether during sample storage, data logging, or chamber control—it may involve more than one site. Managing such stability-related deviations consistently across all locations is critical for regulatory compliance and product integrity.
Click to read the full article.